213248-46-5

Basic information

• Product Name: 1-(pyridin-2-yl)propane-1,3-diol
• Synonyms: 1-(pyridin-2-yl)propane-1,3-diol;1-(2-pyridinyl)-1,3-Propanediol
• CAS NO: 213248-46-5
• Molecular Formula: C8H11NO2
• Molecular Weight: 153.17844
• Mol File: 213248-46-5.mol

Chemical Properties

• Boiling Point: 343.5±27.0 °C(Predicted)
• Appearance: /
• Density: 1.199±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 13.07±0.20(Predicted)
• CAS DataBase Reference: 1-(pyridin-2-yl)propane-1,3-diol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(pyridin-2-yl)propane-1,3-diol(213248-46-5)
• EPA Substance Registry System: 1-(pyridin-2-yl)propane-1,3-diol(213248-46-5)

Safety Data

• Hazardous Substances Data: 213248-46-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Biotechnology Industries:
1-(pyridin-2-yl)propane-1,3-diol is used as a versatile building block for the synthesis of various pharmaceuticals and fine chemicals. Its propan-1,3-diol functional group and pyridine derivative structure enable the creation of diverse molecules with biological activity, making it an important reagent in these industries.
Used in Drug Development:
1-(pyridin-2-yl)propane-1,3-diol is used as a key intermediate in the development of new drugs and therapeutic agents. Its unique structure allows for the design and synthesis of novel compounds with potential therapeutic properties, contributing to the advancement of pharmaceutical research and drug discovery.

Upstream product

• 91012-91-8 ethyl 3-hydroxy-3-(pyridin-2-yl)-propionate 
• 1121-60-4 pyridine-2-carbaldehyde 
• 100391-74-0 2-(1,3-diacetoxy-propyl)-pyridine 

Relevant articles and documents

Tandem catalysis by lipase in a vinyl acetate-mediated cross-aldol reaction

The lipase Novozym435 (0.6% w/w) was used in tandem with organocatalysts in a first vinyl/isopropenyl acetate-mediated aldol reaction. The reaction was facilitated through the lipase-catalyzed in situ generation of acetaldehyde/acetone. The important features of the present methodology include the mild and facile reaction conditions, regenerability of the lipase, comparatively high yields and minimal side product formation.

A prodrug approach towards the development of tricyclic-based FBPase inhibitors

For the purpose of reducing the strong CYP3A4 inhibitory potency of diamide prodrug 4, cyclic prodrugs of tricyclic-based FBPase inhibitors were synthesized. Extensive SAR studies led to the discovery of pyridine-containing cyclic prodrug 20, which strong

NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES

Novel 2'-C-methyl nucleoside 5 '-monophosphate and 4'-C-methyl nucleoside 5'- monophosphate derivatives, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral inf

Novel 2'-C-methyl nucleoside derivatives

Compounds of Formula I, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral infection are described:

Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes

Pharmaceutical compositions containing an FBPase inhibitor and an insulin sensitizer are provided as well as methods for treating diabetes and diseases responding to increased glycemic control, an improvement in insulin sensitivity, a reduction in insulin levels, or an enhancement of insulin secretion.

Novel phosphonic acid based prodrugs of PMEA and its analogues

Prodrugs of Formula I, their uses, their intermediates, and their method of manufacture are described: 1wherein: M and V are cis to one another and MPO3H2 is a phosphonic acid selected from the group consisting of 9-(2-phosphonylmet

Heteroaromatic compounds containing a phosphonate group that are inhibitors of fructose-1,6-bisphosphatase

FBPase inhibitors of the formula I and X are useful in the treatment of diabetes and other conditions associated with elevated blood glucose or excess glycogen storage.